How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Companion Animal Internal Parasiticide Market
- By Parasite Type: Endoparasiticides, Ectoparasiticides, Broad-spectrum Parasiticides
- By Animal Type: Dogs, Cats, Small Mammals
- By Formulation: Oral Tablets, Topical Spot-ons, Injectables, Chewables
- By Active Ingredient Class: Macrocyclic Lactones, Benzimidazoles, Isoxazolines, Pyrantel Pamoate, Emodepside
- By Distribution Channel: Veterinary Clinics, Pet Specialty Stores, Online Retail, Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Endoparasiticides leads By Parasite Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Companion Animal Internal Parasiticide Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Parasite Type 3
Animal Type 3
Formulation 4
Active Ingredient Class 5
Distribution Channel 4
Companies profiled
Zoetis Inc.
Bayer Animal Health (Elanco)
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Virbac
Merial (now part of Boehringer Ingelheim)
Vetoquinol
Dechra Pharmaceuticals
Huvepharma
Phibro Animal Health Corporation
Norbrook Laboratories
Eli Lilly and Company (Elanco)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Zoetis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bayer Animal Health (Elanco)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boehringer Ingelheim Animal Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ceva Santé Animale
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Virbac
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Merial (now part of Boehringer Ingelheim)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Vetoquinol
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Dechra Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Huvepharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Phibro Animal Health Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Norbrook Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Eli Lilly and Company (Elanco)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →PetMed Express (PetMeds)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Neogen Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →IDEXX Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,490M by 2033 · 9.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Endoparasiticides47.8
- Ectoparasiticides32.8
- Broad-spectrum Parasiticides19.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$396.1M → $849.5M · 10.0%
Europe$276.0M → $540.6M · 8.8%
Asia Pacific$252.0M → $586.6M · 11.1%
Latin America$156.0M → $338.6M · 10.2%
Middle East and Africa$120.0M → $241.5M · 9.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.512026
9.512027
9.522028
9.552029
9.552030
9.562031
9.582032
9.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Zoetis Inc.14.2
- Bayer Animal Health (Elanco)23.4
- Boehringer Ingelheim Animal Health7.9
- Ceva Santé Animale11.6
- Virbac8.1
- Merial (now part of Boehringer Ingelheim)6.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Parasite Type21.0%
Animal Type12.9%
Formulation27.7%
Active Ingredient Class28.0%
Distribution Channel10.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.2
- Europe21.1
- Asia Pacific22.9
- Latin America13.2
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. | 95 | 81 | 93 | 89 | 85 | 75 | 86 |
| Bayer Animal Health (Elanco) | 83 | 91 | 79 | 83 | 80 | 73 | 82 |
| Boehringer Ingelheim Animal Health | 72 | 68 | 80 | 87 | 71 | 84 | 77 |
| Ceva Santé Animale | 58 | 65 | 75 | 57 | 69 | 63 | 65 |
| Virbac | 74 | 55 | 59 | 62 | 71 | 70 | 65 |
| Merial (now part of Boehringer Ingelheim) | 53 | 65 | 70 | 65 | 66 | 51 | 62 |
| Vetoquinol | 52 | 55 | 63 | 61 | 45 | 54 | 55 |
| Dechra Pharmaceuticals | 40 | 58 | 43 | 51 | 51 | 52 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Zoetis Inc.
- Bayer Animal Health (Elanco)
- Boehringer Ingelheim Animal Health
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Zoetis Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Bayer Animal Health (Elanco) | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Boehringer Ingelheim Animal Health | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ceva Santé Animale | − | ◐ | ✓ | − | ◐ | ◐ |
| Virbac | ✓ | ◐ | ◐ | − | − | ✓ |
| Merial (now part of Boehringer Ingelheim) | ◐ | ◐ | ✓ | ◐ | ◐ | − |
| Vetoquinol | − | − | ◐ | − | − | − |
| Dechra Pharmaceuticals | − | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Zoetis Inc.86
2Bayer Animal Health (Elanco)82
3Boehringer Ingelheim Animal Health77
4Ceva Santé Animale65
5Virbac65
6Merial (now part of Boehringer Ingelheim)62
7Vetoquinol55
8Dechra Pharmaceuticals49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Zoetis Inc.Bayer Animal Health (Elanco)
Challenger1
Strong scale, closing on the leaders.
Boehringer Ingelheim Animal Health
Contender3
Focused players with pockets of strength.
Ceva Santé AnimaleVirbacMerial (now part of Boehringer Ingelheim)
Niche2
Specialists in a single segment or region.
VetoquinolDechra Pharmaceuticals
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Parasite Type in North America, then scale across Companion Animal Internal Parasiticide Market — a $247M beachhead inside a $3.91B market.
Beachhead (SOM)$247Mobtainable near-term
Serviceable (SAM)$1.52Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Endoparasiticides
Best fit — highest urgency & budget in Parasite Type.
Economic buyer81 fit
Ectoparasiticides
Strong fit — clear ROI and a fast path to value.
End user68 fit
Broad-spectrum Parasiticides
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Parasite Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Animal Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Formulation
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve19%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Parasite Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Companion Animal Internal Parasiticide Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified23%
Evaluation12%
Closed-won8%
$8.5KCAC
$47KLTV
5.6:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Companion Animal Internal Parasiticide Market is a high-growth opportunity — $6.20B by 2033, compounding at 11.2%.
TAM · 2025$2.66Btoday
TAM · 2033$6.20Bforecast
CAGR11.2%2027–2033
Cumulative$37.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.20BTotal addressable market
SAM$2.18BServiceable available market
SOM$436MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.2% CAGR
Demand compounds through 2033, outpacing GDP across Parasite Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Parasite Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.20BLarge & growingTAM by 2033 at 11.2% CAGR
$2.18BServiceable nowreachable with today’s model
$436MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.83BBear7.3% CAGR
$6.20BBase11.2% CAGR
$7.93BBull14.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Animal Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Companion Animal Internal Parasiticide Market — a $5.75B market by 2033. Plan: grow share from 8.4% to 13.6%.
Market size · 2033$5.75Btotal addressable
Market CAGR10.5%2027–2033
Target share13.6%from 8.4% today
Revenue ambition$781Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 13.6% | Behind |
| Revenue | $529M | $781M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.5% | 43.1% | Behind |
| Customer retention | 90.0% | 95.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Parasite Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Animal Type capability
A defensible second engine — invest in Animal Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Parasite Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Animal Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $80M capacity & capability investment
- Greenlight bolt-on M&A in Animal Type
- Authorise North America expansion plan
- Fund R&D program for Parasite Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Companion Animal Internal Parasiticide Market conversation — a $4.72B market you can size, segment and defend in minutes.
Market size · 2033$4.72Btotal opportunity
Growth6.9%CAGR to 2033
Addressable buyers1,133+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Parasite Type
Goal Grow share in Parasite Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 3 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Zoetis Inc.Bayer Animal Health (Elanco)Boehringer Ingelheim Animal HealthCeva Santé AnimaleVirbacMerial (now part of Boehringer Ingelheim)VetoquinolDechra Pharmaceuticals+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Companion Animal Internal Parasiticide Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Companion Animal Internal Parasiticide Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Cold Remedies Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCold Pain Therapy Product Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportDegenerative Disc Disease Threpeutics Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportDegarelix Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportDeferasirox Tablet Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportAir Dental Contra-Angles Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportClinical Diagnostics PCR Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCorticosteroid Eyedrops Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportChikungunya Fever Drugs Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCell Division Cycle 7 Related Protein Kinase Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCeliac Disease Drug Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportCompanion Animal Internal Dewormer Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.